How to cite: Vickers, Andrew. “Gleason Pattern 4 Quantification as a Replacement for Gleason Scoring.” September 15, 2025. Accessed Oct 2026. https://grandroundsinurology.com/gleason-pattern-4-quantification-as-a-replacement-for-gleason-scoring/
Summary
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center, New York, New York, discusses how Gleason scoring has long been central to prostate cancer diagnosis and management but carries significant limitations, particularly regarding reproducibility and the complexity of interpretation. Dr. Vickers argues that the proportion of Gleason pattern 4 in biopsy samples serves as a more direct and consistent predictor of disease progression compared to composite scores.
Dr. Vickers outlines the evidence supporting this approach, noting that studies demonstrate stronger associations between the percentage of pattern 4 and outcomes such as biochemical recurrence and disease-specific survival. He emphasizes that quantification of pattern 4 can provide a clearer framework for counseling patients and making informed treatment decisions. Importantly, the approach may reduce ambiguity in intermediate-grade disease, where traditional scoring often produces challenges.
Additionally, Dr. Vickers addresses the practical implications of pathology reporting, highlighting that quantitative assessment is feasible in routine practice and aligns with current trends in precision oncology. He also raises the need for standardization to ensure reproducibility across institutions. Dr. Vickers stresses that this methodology is not intended to discard the Gleason system entirely but to refine and improve its clinical utility.
Dr. Vickers underscores that Gleason pattern 4 quantification represents an important step toward more precise and transparent prostate cancer grading. The adoption of this approach may ultimately enhance risk stratification, improve patient communication, and facilitate integration with molecular and imaging biomarkers in the evolving landscape of prostate cancer care.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical cases and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Andrew J. Vickers, PhD, is an Attending Research Methodologist in the Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center in New York, New York. He also serves as a Professor of Healthcare Policy and Research at Weill Cornell Medical College in New York, New York. Dr. Vickers specializes in prostate cancer screening, methodological research on prediction modeling, and empirical research into several forms of alternative medicine, particularly acupuncture.
